報價延遲最少15分鐘:2024/05/16 10:38 EDT
|
|
|
|
|
||||||||||||
|
|
|
|
|
2.36 
|
|
|
| 價值評估 |
|
盈利(現時/預測)
-26.75/-4.13
|
|
企業價值
3.61M
|
| 資產負債 |
|
每股賬面淨值
0.41
|
| 現金流量 |
|
現金流量率
--
|
| 損益表 |
|
收益
--
|
|
每股收益
0.25
|
|
同行比較
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
報價延遲最少15分鐘：2024/05/16 10:38 EDT
同行比較之報價最少15分鐘延遲
|
業務概覽
|
|||
| Cyclacel Pharmaceuticals Inc is a clinical-stage biopharmaceutical company that develops targeted medicines for cancer and other proliferative diseases. The company develops several families of anticancer drugs that act on the cell cycle, including CDK (cyclin-dependent kinase) inhibitors, and PLK (polo-like kinase) inhibitors. The pipeline development programs of the company include fadraciclib, Sapacitabine, and plogosertib. |